Introduction of the EuropASI in Norway: Clinical and research experiences from a cost-effectiveness study

ISSN： 1465-9891

Source： Journal of Substance Use, Vol.9, Iss.3-4, 2004-06, pp. : 141-146

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

EuropASI: A standard in de Sleutel, Belgium

By Raes Veerle Lombaert Geert

Journal of Substance Use, Vol. 9, Iss. 3-4, 2004-06 ,pp. : 196-204

Radcliffe Press

Access to resources Recommend Favorite

The diffusion of the ASI in Denmark: Implementation of a national monitoring system based on the EuropASI

By Vind Leif Hecksher Dorte

Journal of Substance Use, Vol. 9, Iss. 3-4, 2004-06 ,pp. : 156-162

Radcliffe Press

Access to resources Recommend Favorite

An introduction to cost-effectiveness and cost–benefit analysis of pharmacogenomics

By Phillips Kathryn A Veenstra David Bebber Stephanie Van Sakowski Julie

Pharmacogenomics, Vol. 4, Iss. 3, 2003-05 ,pp. : 231-239

Future Medicine

Access to resources Recommend Favorite

Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe

By van den Akker-van Marle M Elske Gurwitz David Detmar Symone B Enzing Christine M Hopkins Michael M Gutierrez de Mesa Emma Ibarreta Dolores

Pharmacogenomics, Vol. 7, Iss. 5, 2006-07 ,pp. : 783-792

Future Medicine

Access to resources Recommend Favorite

Rofecoxib cost-effectiveness study results debated

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 455, 2004-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite